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Abstract 
Background 
Cirrhotic patients with ascites are prone to develop various infectious diseases. This study 
aimed to evaluate the occurrence and effect of major infectious diseases on the mortality of 
cirrhotic patients with ascites. 
Methods 
We reviewed de-identified patient data from the National Health Insurance Database, derived 
from the Taiwan National Health Insurance Program, to enroll 4,576 cirrhotic patients with 
ascites, who were discharged from Taiwan hospitals between January 1, 2004 and June 30, 
2004. We collected patients’ demographic and clinical data, and reviewed diagnostic codes to 
determine infectious diseases and comorbid disorders of their hospitalizations. Patients were 
divided into an infection group and non-infection group and hazard ratios (HR) were 
determined for specific infectious diseases. 
Results 
Of the total 4,576 cirrhotic patients with ascites, 1,294 (28.2%) were diagnosed with 
infectious diseases during hospitalization. The major infectious diseases were spontaneous 
bacterial peritonitis (SBP) (645, 49.8%), urinary tract infection (151, 11.7%), and pneumonia 
(100, 7.7%). After adjusting for patients’ age, gender, and other comorbid disorders, the HRs 
of infectious diseases for 30-day and 90-day mortality of cirrhotic patients with ascites were 
1.81 (1.54-2.11) and 1.60 (1.43-1.80) respectively, compared to those in the non-infection 
group. The adjusted HRs of pneumonia, urinary tract infection (UTI), spontaneous bacterial 
peritonitis (SBP), and sepsis without specific focus (SWSF) were 2.95 (2.05-4.25), 1.32 
(0.86-2.05), 1.77 (1.45-2.17), and 2.19 (1.62-2.96) for 30-day mortality, and 2.57 (1.93-3.42), 
1.36 (1.01-1.82), 1.51 (1.29-1.75), and 2.13 (1.70-2.66) for 90-day mortality, compared to 
those in the non-infection group. 
Conclusion 
Infectious diseases increased 30-day and 90-day mortality of cirrhotic patients with ascites. 
Among all infectious diseases identified, pneumonia carried the highest risk for mortality. 
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Background 
Spontaneous bacterial peritonitis (SBP), pneumonia, and urinary tract infections (UTI) are the 
main infectious diseases found in cirrhotic patients [1-5]. According to a meta-analysis study, 
infections in cirrhotic patients increase mortality about four-fold [6]. SBP is the most 
thoroughly evaluated infection in cirrhotic patients. The prevalence of SBP among overall 
hospitalized patients with cirrhosis and ascites is estimated to 10% to 30% [7,8], and SBP 
accounts for at least 24% of overall bacterial infections [3-5,9,10]. In contrast, pneumonia 
was reported in about 21.4% of patients with end-stage liver disease with mortality rates as 
high as 37-41% [5,6]. In another study, community-acquired pneumonia was responsible for 
about 14.4% mortality in cirrhotic patients [11]. 
The above studies do not identify which infectious disease carried higher mortality in 
cirrhotic patients. In addition, cirrhotic patients develop SBP only when they have ascites. 
Since most cirrhotic patients enrolled in previous studies were unselected, the real effect of 
SBP and pneumonia on the mortality of cirrhotic patients still needs to be thoroughly 
evaluated. It would be more effective to compare the effect of different infectious diseases on 
the mortality of cirrhotic patients by evaluating only cirrhotic patients presenting with ascites. 
The purpose of this study was to determine the occurrence and influence of major infectious 
diseases on 30-day and 90-day overall mortality among cirrhotic patients with ascites. 
Methods 
Database 
This study used patient data from the National Health Insurance Research Database in 
Taiwan, which is established and maintained by the Taiwan National Health Insurance 
Bureau and the National Health Research Institute. The Taiwan National Health Insurance 
program was developed in 1995; it includes all citizens residing in Taiwan and covers more 
than 98% of Taiwan’s population. The details of the database have been described in 
previous studies [12-14]. For the present study, the secondary de-identified database was used 
to identify all patient discharges in Taiwan. The study protocol was evaluated by the National 
Health Research Institute, and the privacy of the health care providers and patients were 
protected. This study was approved by the National Health Research Institute (application 
and agreement number: 100101). 
Study sample 
This retrospective study included patients discharged from Taiwan hospitals with the 
diagnostic code of cirrhosis (ICD-9-CM code 571.5, or 571.2 in the database) between 
January 1, 2004 and June 30, 2004. Patients <30 years old were not included because the 
etiologies of cirrhosis for younger patients were much different from older adult patients. For 
patients who had more than one hospitalization in this period, only the first hospitalization 
was enrolled. Ascites was defined by ICD-9-CM code 789.5, or ICD-9 v3 Procedure Codes 
54.91 in the database. We enrolled only cirrhotic patients with the diagnostic codes for ascites 
in their hospitalizations in the present study. For each patient enrolled, the starting point for 
evaluating the 30-day and 90-day mortality was the patients’ date of admission in enrolled 
hospitalization. 
A total of 4,576 cirrhotic patients with ascites were identified and enrolled in this study. The 
patients were classified into an infection group and non-infection group according to the 
presence of infectious diseases or not in their enrolled hospitalizations. We reviewed all 
diagnostic codes of the enrolled patients to evaluate if they had infectious disease or not 
during their hospitalizations. The main infectious diseases in our study included pneumonia 
(ICD-9-CM codes 481–487, without 484), sepsis (ICD-9-CM codes 038, 020.0, 790.7, or 
112.81) [15], urinary tract infection (UTI) (ICD-9-CM codes 590.1, 595.0, 595.9 or 599.0), 
and SBP. As in previous studies, SBP was defined as a patient with the ICD-9-CM diagnosis 
codes for both cirrhosis and peritonitis (codes 567.2, 567.8, or 567.9) [14,16,17]. In order to 
exclude secondary peritonitis, patients with other causes of peritonitis (such as appendicitis, 
ischemic bowel disease, biliary tract or hollow organ perforation), as well as those having an 
additional procedure code for abdominal surgery, were not included [14,16,17]. When 
patients had diagnostic codes of sepsis without other diagnostic codes for infectious focus, 
including catheter-related sepsis, they were considered to have sepsis without specific focus 
(SWSF). Other infectious diseases included cellulitis (ICD-9-CM code 681 or 682), biliary 
tract infection or acute cholecystitis (ICD-9-CM codes 576.1, 575.0, 574.00, 574.01, 574.30, 
574.31, 574.60, 574.61, 574.80, 574.81), empyema (ICD-9-CM code 510), necrotizing 
fasciitis (ICD-9-CM code 728.86), septic arthritis (ICD-9-CM code 711), infective 
endocarditis (ICD-9-CM code 421), and other bacterial infections. A national mortality 
database was used to identify the dates of death and calculate patients’ overall 30-day and 90-
day mortality. 
Statistical analyses 
Cox hazard regressions were performed to evaluate the effect of infectious diseases on 
mortality in cirrhotic patients with ascites. Comorbid medical disorders selected for 
regression included age, gender, alcoholism (ICD-9-CM codes 291, 303, 305.00-305.03, 
571.0-571.3), hepatocellular carcinoma (HCC) (ICD-9-CM code 155.0), hepatic 
encephalopathy (HE) (ICD-9-CM code 572.2), esophageal variceal bleeding (EBV) (ICD-9-
CM codes 456.0, 456.20), renal function impairment (RFI) (ICD-9-CM codes 582, 585, 586, 
or 572.4), and peptic ulcer bleeding (PUB) (ICD-9-CM codes 531.0, 531.2, 531.4, 531.6, 
532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4 and 533.6) [18]. Cox proportional hazard 
regressions were also performed to evaluate the effects of main infectious diseases on the 
mortality of cirrhotic patients with ascites compared to mortality in non-infection group. The 
Student’s t test was used to compare continuous variables, and the Chi square test was used to 
compare categorical variables. Hazard ratios (HR) and 95% confidence intervals (CI) using a 
significance level of 0.05 for this study were also calculated. The SPSS statistical package 
SPSS System for Windows, version 13.0 (SPSS, Chicago, IL, USA) was used to perform the 
analyses in this study. 
Results 
Of the total 4,576 cirrhotic patients with ascites, mean age was 58.6 ± 13.7 years. There were 
3,165 (69.2%) male patients and 1,411 (30.8%) female patients. During their enrolled 
hospitalizations, 1,294 patients had co-existence of infectious diseases and 3,282 did not. The 
clinical characteristics of both groups are shown in Table 1. More male patients were found 
in the non-infection group (66.2% vs. 70.4%, P = 0.006). Patients were aged 59.0 ± 13.8 
years in the infection group and 58.4 ± 13.6 years in the non-infection group. No statistically 
significant differences were found between the both groups (P = 0.169). More patients with 
HCC were noted in the non-infection group than in the infection group (27.4% vs. 19.9%; P < 
0.001). More patients had EVB in the non-infection group than in the infection group (14.5% 
vs. 10.2%; P < 0.001). More patients had alcohol-related cirrhosis in the non-infection group 
than in the infection group (20.6% vs. 17.9%; P = 0.039). Other factors, including HE, PUB, 
and RFI, were not different between the two groups. 
Table 1 Comparison of demographic characteristics of the infection group (n = 1,294) 
and non-infection group (n = 3,282) 
 Infection  
(n = 1294) 
Non-infection  
(n = 3282) 
P value 
Male, no. (%) 856 (66.2) 2309 (70.4) 0.006 
Age, yr   0.169 
 30–44, no. (%) 219 (16.9) 572 (17.4)  
 45–59, no. (%) 458 (35.4) 1154 (35.2)  
 60–74, no. (%) 410 (31.7) 1100 (33.5)  
 >75, no. (%) 207 (16.0) 456 (13.9)  
HCC, no. (%) 258 (19.9) 898 (27.4) <0.001 
Esophageal variceal bleeding 132 (10.2) 476 (14.5) <0.001 
Hepatic encephalopathy 218 (16.8) 488 (14.9) 0.095 
PUB, no. (%) 64 (4.9) 192 (5.9) 0.231 
Alcoholism, no. (%) 232 (17.9) 677 (20.6) 0.039 
RFI, no. (%) 103 (8.0) 210 (6.4) 0.060 
Abbreviations: HCC, hepatocellular carcinoma; PUB, peptic ulcer bleeding; RFI, renal 
function impairment. 
Mortality in the two groups is shown in Table 2. In the non-infection group, the 30-day and 
90-day mortality rates of cirrhotic patients with ascites were 12.7% and 26.0%, respectively. 
In the infection group, the 30-day and 90-day mortality rates of cirrhotic patients with ascites 
were 19.9% and 35.1%, respectively. The infection group included 645 (49.8%) patients with 
SBP, 188 (14.5%) patients with SWSF, 151 (11.7%) patients with UTI, and 100 (7.7%) 
patients with pneumonia. The remaining 210 (16.2%) patients had other infectious diseases or 
dual infections during their hospitalizations. The 30-day mortality rates of patients with SBP, 
SWSF, UTI, and pneumonia were 19.7%, 25.5%, 14.6%, and 32.0%, respectively. The 90-
day mortality rates of patients with SBP, SWSF, UTI, and pneumonia were 33.5%, 44.7%, 
31.8%, and 51.0%, respectively. Compared to SBP, pneumonia had higher 30-day (32.0% vs. 
19.7%, P = 0.005) and 90-day (51.0% vs. 33.5%, P = 0.001) mortality. 
Table 2 Comparison of 30-day and 90-day mortality of the infection group and non-
infection group 
Infections Number (%) 30-day mortality 90-day mortality 
No 3282 (71.7) 12.7% 26.0% 
Yes 1294 (28.3) 19.9% 35.1% 
SBP 645 (49.8) 19.7% 33.5% 
UTI 151 (11.7) 14.6% 31.8% 
Pneumonia 100 (7.7) 32.0% 51.0% 
SWSF 188 (14.5) 25.5% 44.7% 
Others 210 (16.2) 13.8% 26.2% 
Abbreviations: SBP, spontaneous bacterial peritonitis; UTI, urinary tract infection; SWSF, 
sepsis without specific focus. 
In order to alleviate the effects of other confounding factors, we used the Cox regression 
model to adjust the HRs of infectious diseases for the mortality of cirrhotic patients with 
ascites. Results are listed in Table 3. After adjusting for patients’ gender, age, and other 
medical comorbid disorders, the HRs of infectious diseases for 30-day and 90-day mortality 
were 1.81 (95% CI, 1.54-2.11; P < 0.001) and 1.60 (95% CI, 1.43-1.80; P < 0.001), 
respectively. Other risk factors for 30-day mortality of cirrhotic patients with ascites included 
age (HR, 1.02; 95% CI, 1.02-1.03, P < 0.001), male gender (HR, 1.49; 95% CI, 1.25-1.77; P 
< 0.001), RFI (HR, 2.70; 95% CI, 2.19-3.35; P < 0.001), EVB (HR, 1.52; 95% CI, 1.23-1.87; 
P < 0.001), HCC (HR, 2.30; 95% CI, 1.96-2.70; P < 0.001), and HE (HR, 1.28; 95% CI, 1.05-
1.56; P = 0.013). Other risk factors for 90-day mortality of cirrhotic patients with ascites 
included age group (HR, 1.02; 95% CI, 1.02-1.03, P < 0.001), male gender (HR, 1.24; 95% 
CI, 1.09-1.40; P = 0.001), RFI (HR, 2.11; 95% CI, 1.78-2.51; P < 0.001), EVB (HR, 1.21; 
95% CI, 1.03-1.43; P = 0.024), HCC (HR, 2.54; 95% CI, 2.26-2.84; P < 0.001), and HE (HR, 
1.34; 95% CI, 1.16-1.54; P < 0.001). Alcohol-related cirrhosis correlated negatively with the 
30-day and 90-day mortality of cirrhotic patients with ascites (HR, 0.77 and 0.78; 95% CI, 
0.60-1.00 and 0.65-0.93; P, 0.045 and 0.007). 
Table 3 Adjusted hazard ratios of risk factors for 30-day and 90-day mortality in 
cirrhotic patients with ascites 
 30-day mortality 90-day mortality 
Variable HR (95% CI) P value HR (95% CI) P value 
Infection 1.81 (1.54-2.11) <0.001 1.60 (1.43-1.80) <0.001 
Age 1.02 (1.02-1.03) <0.001 1.02 (1.02-1.03) <0.001 
Male 1.49 (1.25-1.77) <0.001 1.24 (1.09-1.40) 0.001 
RFI 2.70 (2.19-3.35) <0.001 2.11 (1.78-2.51) <0.001 
Alcoholism 0.77 (0.60-1.00) 0.045 0.78 (0.65-0.93) 0.007 
EVB 1.52 (1.23-1.87) <0.001 1.21 (1.03-1.43) 0.024 
HCC 2.30 (1.96-2.70) <0.001 2.54 (2.26-2.84) <0.001 
PUB 1.16 (0.84-1.60) 0.374 1.13 (0.89-1.43) 0.322 
HE 1.28 (1.05-1.56) 0.013 1.34 (1.16-1.54) <0.001 
Abbreviations: HR, hazard ratio; CI, confidence interval; RFI, renal function impairment; 
EVB, esophageal variceal bleeding; HCC, hepatocellular carcinoma; PUB, peptic ulcer 
bleeindg; HE, hepatic encephalopathy. 
In order to compare the effect of different infectious diseases on the mortality of cirrhotic 
patients with ascites, we used the Cox regression model to adjust the HRs of different 
infectious diseases according to other confounding factors, including age group, gender, RFI, 
alcoholism, EVB, HCC, PUB, and HE. Results are shown in Table 4. Compared to the non-
infection group, the adjusted HR of SBP, pneumonia, UTI, and SWSF was 1.77 (95% CI, 
1.45-2.17; P < 0.001), 2.95 (95% CI, 2.02-4.25; P < 0.001), 1.32 (95% CI, 0.86-2.05; P = 
0.207), and 2.19 (95% CI, 1.62-2.96; P < 0.001) for 30-day mortality. For 90-day mortality, 
the respective adjusted HRs were 1.51(95% CI, 1.29-1.75; P < 0.001), 2.57 (95%, 1.93-3.42; 
P < 0.001), 1.36 (95% CI, 1.01-1.82; P = 0.044), and 2.13 (95% CI, 1.70-2.66; P < 0.001). 
Pneumonia was responsible for the highest mortality risk among cirrhotic patients with 
ascites. Figure 1 shows the cumulative survival plot for cirrhotic patients with ascites with 
and without different infectious diseases. 
Table 4 Adjusted hazard ratios (HR) of different types of infectious diseases for 
mortality of cirrhotic patients with ascites, compared with non-infection group 
 30-day mortality 90-day mortality 
Variables HR (95% CI) P value HR (95% CI) P value 
Pneumonia 2.95 (2.05-4.25) <0.001 2.57 (1.93-3.42) <0.001 
UTI 1.32 (0.86-2.05) 0.207 1.36 (1.01-1.82) 0.044 
SBP 1.77 (1.45-2.17) <0.001 1.51 (1.29-1.75) <0.001 
SWSF 2.19 (1.62-2.96) <0.001 2.13 (1.70-2.66) <0.001 
Others 1.56 (1.06-2.28) 0.023 1.34 (1.02-1.76) 0.039 
Abbreviations: SBP, spontaneous bacterial peritonitis; UTI, urinary tract infection; SWSF, 
sepsis without specific focus. 
Figure 1 Cumulative survival plot for cirrhotic patients with ascites with and without 
the presence of different infectious diseases. After Cox regression model, the hazard ratios 
of pneumonia, urinary tract infection (UTI), spontaneous bacterial peritonitis (SBP), sepsis 
without specific focus (SWSF), and other infectious diseases for 90-day mortality were 2.57 
(1.93-3.42), 1.36 (1.01-1.82), 1.51 (1.29-1.75), 2.13 (1.70-2.66), and 1.34(1.02-1.76) 
compared to non-infection group. 
Discussion 
Cirrhotic patients are prone to develop infectious diseases because of their underlying 
immune compromised status. In previous studies, SBP comprised about 20-30% of infectious 
diseases in cirrhotic patients [3-5]. However, most of these studies included a cirrhotic 
population without ascites. According to the results of the nationwide population-based 
database used in our study, about 28.3% of cirrhotic in-patients with ascites had infectious 
diseases, of which SBP comprised about 50%. Accordingly, when cirrhotic patients with 
ascites have septic signs, clinical physicians should consider SBP as a top candidate for 
infectious focus. 
In the present study, pneumonia had the highest risk for mortality among cirrhotic patients 
with ascites, which was about 3-fold increased compared to the mortality of cirrhotic patients 
without infectious diseases. A previous study showed cirrhotic patients with pneumonia 
caused by Staphylococcus aureus had higher pneumonia severity index classes and 
demonstrated a higher mortality rate than non-cirrhotic patients [19]. Among pathogens for 
pneumonia in cirrhotic patients, the most frequent pathogen for community-acquired 
pneumonia is still Streptococcus pneumonia, and the predominant pathogens for hospital-
acquired pneumonia are gram-negative bacilli and staphylococci [20]. This latter result is the 
same as that for pneumonia in non-cirrhotic patients, indicating that the pathogenesis of 
pneumonia in cirrhotic patients is not different from that in non-cirrhotic patients. Defects in 
innate pulmonary defenses caused by cirrhosis may explain why pneumonia contributes to 
the high mortality among cirrhotic patients [21,22]. Innate immunity is necessary for 
clearance of pathogens in patients with pneumonia even if they receive antibiotics [21-25]. 
High mortality of pneumonia in cirrhotic patients may be attributed to the poor ability of their 
innate immunity to clear the pathogens associated with pneumonia. 
Because of the high mortality associated with pneumonia in cirrhotic patients, it is important 
for development of pneumonia to be avoided in these patients. Hepatic encephalopathy and 
tracheal intubations are usually considered to be risk factors for the development of 
pneumonia in cirrhotic patients. In addition, influenza infection can lead to hepatic 
decompensation, resulting in severe secondary bacterial pneumonia in cirrhotic patients 
[26,27]. In addition, plasma-based blood products increase transfusion-associated acute lung 
injury, which affects lung clearance and patients receiving these blood products are prone to 
develop pneumonia; red blood cell transfusions also increase the rate of pneumonia [28]. In 
order to prevent cirrhotic patients from developing pneumonia, it is critical to avoid needless 
transfusions and to prevent influenza infections. 
In the present study, we found that SWSF also contributed to higher mortality among 
cirrhotic patients with ascites. We considered that this kind of infection was caused by a 
failure of patients’ defense mechanisms to prevent the microorganisms in the intestinal lumen 
from reaching the systemic circulation. When SWSF occurs, it means that the cirrhotic 
patients will have a tendency toward bacterial translocation from the intestinal lumen and 
poor clearance of bacteria in their bloodstream. This phenomenon may contribute to higher 
mortality among cirrhotic patients with ascites. 
The very large sample size in the present study provided the statistical power to detect 
different effects of various infectious diseases on the mortality of cirrhotic patients with 
ascites. Nonetheless, some limitations of this study must be noted. First, although the severity 
of liver cirrhosis is commonly based by Child-Pugh scores or MELD scores, the database 
used in the present study did not allow us to identify the laboratory for bilirubin, albumin, 
creatinine, or prothrombin time by ICD-9 coding numbers. However, is has been proposed 
recently that the stages of cirrhosis are separated by easily defined clinical criteria [29]. The 
concept of four clinical stages of cirrhosis has been identified, and each stage has distinct 
clinical features and a markedly different prognosis. Cirrhotic patients with ascites are 
actually in decompensated status and are at least in stage 3 of the disease. On the other hand, 
complications of cirrhosis, such as EBV, HE, HCC, and RFI were considered in this study. 
Hence, we believe that lacking specific lab data is not a major flaw in this study, because all 
cases were reviewed in stage 3 according to the clinical staging system, and the other 
complications (such as EBV, HE, HCC, and RFI) were also well classified. Secondly, the 
exact etiology of liver cirrhosis was not identified in this national population-based study 
although nearly 20% of cirrhotic patients had alcohol-related cirrhosis. However, the etiology 
of liver cirrhosis in Taiwan has been well established in numerous published reports and is 
known to be related to the hepatitis B virus. However, the etiology of non-alcohol related 
liver cirrhosis cannot be confirmed definitively as a prognostic factor. Thirdly, the type of 
acquisition of infection is important in understanding the mortality of infection. 
Unfortunately, we were not able to identify exactly if the infections were community-
acquired or hospital-acquired. Fourthly, systemic inflammatory response syndrome (SIRS) is 
considered to be a negative prognostic factor in patients with advanced cirrhosis [30]. Due to 
the limitations of our database, we could not identify if the cirrhotic patients had SIRS during 
their hospitalizations. Finally, even using this database, we could not identify sufficient 
numbers of other rare infectious diseases for comparison, including necrotizing fasciitis, 
meningitis, infective endocarditis, etc. However, these infections may have less clinical 
significance because of the limited number of cases encountered in clinical practice. Despite 
these limitations, this study is the first complete nationwide population-based study for 
identifying the occurrence and mortality risk of major infections in cirrhotic patients with 
ascites. 
Conclusions 
In summary, the presence of infectious diseases increases 30-day mortality about 1.8-fold in 
cirrhotic patients with ascites. SBP is responsible for nearly half of infections in cirrhotic 
patients with ascites. Pneumonia carries the highest risk for overall 30-day and 90-day 
mortality among cirrhotic patients with ascites. 
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